CL2017001457A1 - Régimen de dosificación para un agonista selectivo del receptor s1p1. - Google Patents
Régimen de dosificación para un agonista selectivo del receptor s1p1.Info
- Publication number
- CL2017001457A1 CL2017001457A1 CL2017001457A CL2017001457A CL2017001457A1 CL 2017001457 A1 CL2017001457 A1 CL 2017001457A1 CL 2017001457 A CL2017001457 A CL 2017001457A CL 2017001457 A CL2017001457 A CL 2017001457A CL 2017001457 A1 CL2017001457 A1 CL 2017001457A1
- Authority
- CL
- Chile
- Prior art keywords
- selective
- receptor agonist
- dosing regimen
- propilimino
- tiazolidin
- Prior art date
Links
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE RELACIONA CON UN RÉGIMEN DE DOSIFICACIÓN PARA (R)-5-[3-CLORO-4-(2,3-DIHIDROXI-PROPOXI)-BENZ[Z]ILIDEN]-2-([Z]PROPILIMINO)-3-O-TOLIL-TIAZOLIDIN-4-ONA.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2014077469 | 2014-12-11 | ||
| EP2015058202 | 2015-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001457A1 true CL2017001457A1 (es) | 2018-02-09 |
Family
ID=54843844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001457A CL2017001457A1 (es) | 2014-12-11 | 2017-06-08 | Régimen de dosificación para un agonista selectivo del receptor s1p1. |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US10220023B2 (es) |
| EP (2) | EP4056179A1 (es) |
| JP (1) | JP6244497B1 (es) |
| KR (4) | KR20230147768A (es) |
| CN (2) | CN117137912A (es) |
| AU (2) | AU2015359346B2 (es) |
| CA (1) | CA2968180C (es) |
| CL (1) | CL2017001457A1 (es) |
| CY (1) | CY1125170T1 (es) |
| DK (1) | DK3256125T3 (es) |
| EA (1) | EA036075B1 (es) |
| ES (1) | ES2909071T3 (es) |
| FR (1) | FR22C1021I2 (es) |
| HR (1) | HRP20220359T8 (es) |
| HU (2) | HUE057865T2 (es) |
| IL (1) | IL252727B (es) |
| LT (2) | LT3256125T (es) |
| LU (1) | LUC00262I2 (es) |
| MX (2) | MX2020011182A (es) |
| MY (1) | MY188764A (es) |
| NL (1) | NL301174I2 (es) |
| NO (1) | NO2022023I1 (es) |
| PH (1) | PH12017501059A1 (es) |
| PL (1) | PL3256125T3 (es) |
| PT (1) | PT3256125T (es) |
| RS (1) | RS63048B1 (es) |
| SG (1) | SG11201704563RA (es) |
| SI (1) | SI3256125T1 (es) |
| SM (1) | SMT202200137T1 (es) |
| TW (1) | TW201625242A (es) |
| UA (1) | UA122064C2 (es) |
| WO (1) | WO2016091996A1 (es) |
| ZA (1) | ZA201704624B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101718639B1 (ko) | 2008-03-17 | 2017-03-21 | 액테리온 파마슈티칼 리미티드 | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 |
| WO2016091996A1 (en) * | 2014-12-11 | 2016-06-16 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective s1p1 receptor agonist |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| AU2020316640A1 (en) | 2019-07-22 | 2022-03-03 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
| PH12022551043A1 (en) | 2019-10-31 | 2023-05-03 | Idorsia Pharmaceuticals Ltd | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
| US20230123588A1 (en) | 2020-03-06 | 2023-04-20 | Actelion Pharmaceuticals Ltd | Methods of slowing brain volume loss |
| CA3213818A1 (en) | 2021-03-17 | 2022-09-22 | Actelion Pharmaceuticals Ltd | Pharmaceutical dosage system |
| WO2023062511A1 (en) | 2021-10-11 | 2023-04-20 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
| WO2023061918A1 (en) | 2021-10-11 | 2023-04-20 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
| US12357616B2 (en) | 2021-10-11 | 2025-07-15 | Vanda Pharmaceuticals Inc. | Methods of treating multiple sclerosis |
| US20230144895A1 (en) | 2021-10-11 | 2023-05-11 | Actelion Pharmaceuticals Ltd | Methods Of Treating Multiple Sclerosis |
| EP4426296A1 (en) | 2021-11-05 | 2024-09-11 | Actelion Pharmaceuticals Ltd | Methods for treating multiple sclerosis |
| WO2023152290A1 (en) | 2022-02-11 | 2023-08-17 | Actelion Pharmaceuticals Ltd | Methods of slowing an increase in brain ventricular volume |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
| US7538135B2 (en) | 2003-07-08 | 2009-05-26 | Novartis Ag | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds |
| EP2295418A1 (en) | 2003-11-21 | 2011-03-16 | Actelion Pharmaceuticals Ltd. | 5-(benz-(z)-ylidene)-thiazolidin-4-one derivatives as immunosuppressant agents |
| USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| EP1718604A4 (en) | 2004-02-24 | 2008-02-13 | Irm Llc | COMPOUNDS AND COMPOSITIONS OF IMMUNOSUPPRESSANTS |
| ES2525497T3 (es) | 2004-10-08 | 2015-10-09 | Forward Pharma A/S | Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico |
| KR20130041385A (ko) | 2004-11-29 | 2013-04-24 | 노파르티스 아게 | Ｓ１ｐ 수용체 효능제의 투여 용법 |
| US7879821B2 (en) | 2006-01-26 | 2011-02-01 | University Of Medicine And Dentistry Of New Jersey | Method for modulating inflammatory responses by altering plasma lipid levels |
| DK2094676T3 (da) | 2006-11-23 | 2013-06-10 | Actelion Pharmaceuticals Ltd | Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater |
| US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| ES2916604T1 (es) | 2007-02-08 | 2022-07-04 | Biogen Ma Inc | Ensayos de detección de nrf2 y métodos y composiciones relacionados |
| KR101718639B1 (ko) | 2008-03-17 | 2017-03-21 | 액테리온 파마슈티칼 리미티드 | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 |
| RU2554347C2 (ru) | 2008-08-19 | 2015-06-27 | Ксенопорт, Инк. | Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения |
| EP2177521A1 (en) | 2008-10-14 | 2010-04-21 | Almirall, S.A. | New 2-Amidothiadiazole Derivatives |
| GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| US20100160369A1 (en) | 2008-12-04 | 2010-06-24 | Exelixis, Inc. | S1P1 Agonists and Methods of Making And Using |
| HRP20151190T1 (hr) | 2008-12-22 | 2016-01-01 | Novartis Ag | Režim doziranja za fingolimod u lijeäśenju multiple skleroze |
| JP5657565B2 (ja) | 2008-12-22 | 2015-01-21 | ノバルティス アーゲー | Ｓ１ｐ受容体アゴニストの投与レジメン |
| EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| DK2379063T4 (da) | 2009-01-09 | 2021-05-25 | Fwp Ip Aps | Farmaceutisk præparat omfattende en eller flere fumarsyreestere i en erosionsmatrix |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| DE102010048788A1 (de) | 2009-02-13 | 2011-05-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| DE102009008851A1 (de) | 2009-02-13 | 2010-08-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| US20100260755A1 (en) | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
| EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
| BR112012013092A2 (pt) | 2009-12-01 | 2016-10-25 | Metanomics Health Gmbh | ''métodos de diagnóstico, método para identificar se um indivíduo necessita de uma terapia contra esclerose múltipla, métodos de determinação e previsão relacionados à esclerose múltipla'' |
| EP2343287A1 (en) | 2009-12-10 | 2011-07-13 | Almirall, S.A. | New 2-aminothiadiazole derivatives |
| DE102010026879A1 (de) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
| EP2366702A1 (en) | 2010-03-18 | 2011-09-21 | Almirall, S.A. | New oxadiazole derivatives |
| EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| EP2455080A1 (en) | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
| SG195049A1 (en) | 2011-05-26 | 2013-12-30 | Biogen Idec Inc | Methods of treating multiple sclerosis and preserving and/or increasing myelin content |
| JP2014517300A (ja) | 2011-05-31 | 2014-07-17 | メタノミクス ヘルス ゲーエムベーハー | 多発性硬化症を診断する方法 |
| WO2013119677A1 (en) | 2012-02-07 | 2013-08-15 | Biogen Idec Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
| US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| US20130314669A1 (en) | 2012-05-24 | 2013-11-28 | Hadasit Medical Research Services And Development Ltd. | Method and system for assessing visual disorder |
| JP6324380B2 (ja) | 2012-07-27 | 2018-05-16 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ｓ１ｐ調節剤および／またはａｔｘ調節剤である化合物 |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| WO2014025709A1 (en) | 2012-08-06 | 2014-02-13 | Biogen Idec Ma Inc. | Compounds that are s1p modulating agents and/or atx modulating agents |
| EP2879674B1 (en) | 2012-08-06 | 2017-11-22 | Biogen MA Inc. | Compounds that are s1p modulating agents and/or atx modulating agents |
| US20150220693A1 (en) | 2012-08-13 | 2015-08-06 | Biogen Idec Ma Inc. | Disease progression parameters and uses thereof for evaluating multiple sclerosis |
| SI2885266T1 (sl) | 2012-08-17 | 2020-10-30 | Actelion Pharmaceuticals Ltd | Postopek za pripravo (2Z,5Z)-5-(3-kloro-4-((R)-2,3-dihidroksipropoksi) benziliden)-2-(propilimino)-3-(O-tolil)tiazolidin-4-on in v omenjenem postopku uporabljena vmesna spojina |
| US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| US20140056973A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug |
| CN104870014A (zh) | 2012-10-09 | 2015-08-26 | 比奥根Ma公司 | 联合治疗及用于治疗脱髓鞘病症的用途 |
| WO2014071371A1 (en) | 2012-11-05 | 2014-05-08 | Xenoport, Inc. | Cocrystals of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| DK2970101T4 (da) | 2013-03-14 | 2025-11-17 | Alkermes Pharma Ireland Ltd | Pro-drugs af fumarater og deres anvendelse i behandling af forskellige sygdomme |
| WO2015066515A1 (en) | 2013-11-01 | 2015-05-07 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| WO2016091996A1 (en) * | 2014-12-11 | 2016-06-16 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective s1p1 receptor agonist |
-
2015
- 2015-12-10 WO PCT/EP2015/079208 patent/WO2016091996A1/en not_active Ceased
- 2015-12-10 KR KR1020237034975A patent/KR20230147768A/ko not_active Ceased
- 2015-12-10 PL PL15807916T patent/PL3256125T3/pl unknown
- 2015-12-10 UA UAA201707086A patent/UA122064C2/uk unknown
- 2015-12-10 KR KR1020177018950A patent/KR102427123B1/ko active Active
- 2015-12-10 KR KR1020217032617A patent/KR102590068B1/ko active Active
- 2015-12-10 AU AU2015359346A patent/AU2015359346B2/en active Active
- 2015-12-10 SI SI201531811T patent/SI3256125T1/sl unknown
- 2015-12-10 RS RS20220283A patent/RS63048B1/sr unknown
- 2015-12-10 SM SM20220137T patent/SMT202200137T1/it unknown
- 2015-12-10 SG SG11201704563RA patent/SG11201704563RA/en unknown
- 2015-12-10 MY MYPI2017702097A patent/MY188764A/en unknown
- 2015-12-10 HR HRP20220359TT patent/HRP20220359T8/hr unknown
- 2015-12-10 PT PT158079160T patent/PT3256125T/pt unknown
- 2015-12-10 ES ES15807916T patent/ES2909071T3/es active Active
- 2015-12-10 JP JP2017531167A patent/JP6244497B1/ja active Active
- 2015-12-10 LT LTEPPCT/EP2015/079208T patent/LT3256125T/lt unknown
- 2015-12-10 US US15/534,929 patent/US10220023B2/en active Active
- 2015-12-10 CN CN202310732054.6A patent/CN117137912A/zh active Pending
- 2015-12-10 EA EA201791286A patent/EA036075B1/ru unknown
- 2015-12-10 CA CA2968180A patent/CA2968180C/en active Active
- 2015-12-10 HU HUE15807916A patent/HUE057865T2/hu unknown
- 2015-12-10 EP EP22152212.1A patent/EP4056179A1/en active Pending
- 2015-12-10 EP EP15807916.0A patent/EP3256125B1/en active Active
- 2015-12-10 MX MX2020011182A patent/MX2020011182A/es unknown
- 2015-12-10 KR KR1020207002611A patent/KR20200013086A/ko not_active Ceased
- 2015-12-10 DK DK15807916.0T patent/DK3256125T3/da active
- 2015-12-10 MX MX2017007638A patent/MX379273B/es unknown
- 2015-12-10 TW TW104141578A patent/TW201625242A/zh unknown
- 2015-12-10 CN CN201580067209.2A patent/CN106999461A/zh active Pending
-
2017
- 2017-06-06 IL IL252727A patent/IL252727B/en active IP Right Grant
- 2017-06-07 PH PH12017501059A patent/PH12017501059A1/en unknown
- 2017-06-08 CL CL2017001457A patent/CL2017001457A1/es unknown
- 2017-07-10 ZA ZA2017/04624A patent/ZA201704624B/en unknown
-
2019
- 2019-01-29 US US16/261,327 patent/US10857134B2/en active Active
-
2020
- 2020-04-22 AU AU2020202684A patent/AU2020202684A1/en not_active Abandoned
- 2020-11-05 US US17/090,756 patent/US11771683B2/en active Active
-
2022
- 2022-04-07 CY CY20221100260T patent/CY1125170T1/el unknown
- 2022-05-09 NL NL301174C patent/NL301174I2/nl unknown
- 2022-05-12 HU HUS2200021C patent/HUS2200021I1/hu unknown
- 2022-05-13 LU LU00262C patent/LUC00262I2/fr unknown
- 2022-05-20 LT LTPA2022505C patent/LTC3256125I2/lt unknown
- 2022-06-01 FR FR22C1021C patent/FR22C1021I2/fr active Active
- 2022-06-10 NO NO2022023C patent/NO2022023I1/no unknown
- 2022-10-13 US US18/046,492 patent/US12336980B2/en active Active
-
2025
- 2025-05-23 US US19/216,912 patent/US20250281463A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001457A1 (es) | Régimen de dosificación para un agonista selectivo del receptor s1p1. | |
| CY2022011I2 (el) | Δοσολογικο σχημα για την πονεσιμοδη, εναν επιλεκτικο αγωνιστη του υποδοχεα s1p1 | |
| DK3762380T3 (da) | Phenylpyrrolidinon-formylpeptid-2-receptoragonister | |
| DK3368060T3 (da) | Glugacon-receptor-agonister | |
| MX2017001079A (es) | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). | |
| LT3190113T (lt) | Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai | |
| CL2013003686A1 (es) | Compuestos derivados de ergolina, antagonista del receptor de 5-ht1d; útiles para el tratamiento de la migraña. | |
| DK3325487T3 (da) | Formulering til bløde, anticholinerge analoger | |
| MA40858A (fr) | Composés antagonistes des récepteurs d3 à la dopamine | |
| LT3347360T (lt) | Junginiai, naudingi ror-gama-t slopinimui | |
| IL253524A0 (en) | Tube holder for a filling machine | |
| EP3372553A4 (en) | BOTTLE CONVEYOR, BOTTLE GRIPPING MECHANISM, BOTTLE GRIP ASSEMBLY FOR FILLING MACHINE | |
| DK3250549T3 (da) | Cyclopropylmethanaminer som selektive 5-HT(2C)-receptoragonister | |
| EP3592534A4 (en) | DOSING MECHANISMS FOR 3D PRINTERS | |
| EP3321536A4 (en) | MECHANISM FOR PROGRESSIVE BRAKING | |
| HK1248524A1 (en) | Dosing regimen for a selective s1p1 receptor agonist | |
| TH1601000316A (th) | อะโกนิสต์ของตัวรับวาโซเพรสซิน-2 | |
| TH1401006488B (th) | เครื่องกลเพื่อการบรรจุแบบลูกสูบ |